Please assess the completion status of the following clinical trial:

Trial Title: Inner-City Anti-IgE Therapy for Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Both body weight and total serum IgE suitable for omalizumab dosing.~* Diagnosis of asthma made by a physician more than 1 year prior to study entry OR diagnosis of asthma made less than 1 year prior to study entry but have had asthma symptoms for longer than 1 year prior to study entry~* Are receiving long-term asthma control therapy OR have symptoms consistent with persistent asthma OR have evidence of uncontrolled disease~* Positive prick skin test to at least one perennial allergen (e.g., dust mite, cockroach, mold, cat, dog, rat, mouse)~* Live in a preselected zip code are~* Able to perform spirometry measurements~* Willing to sign informed consent or have parent or guardian willing to provide informed consent~* Previously had chicken pox or received varicella (chicken pox) vaccine~* Have some form of health care insurance that covers costs of medications~Exclusion Criteria:~If participant meets any of these criteria, they are not eligible at that time but may be reassessed:~* Systemic prednisone (or equivalent) during the 2 weeks prior to Visit 2~* Systemic prednisone (or equivalent) for more than 30 of the 60 days prior to study entry~* Pregnancy or breastfeeding~* Acute sinusitis or chest infection requiring antibiotics within 1 month of study screening~* Currently participating in another asthma-related clinical trial or have previously participated in an another asthma-related trial within 1 month of study entry~* Does not sleep at least 4 nights per week in one home~* Lives with a foster parent~* Does not have access to a phone~* Plans to move during the study~* Previously treated with anti-IgE therapy within 1 year of study entry~* Currently receiving or received hyposensitization therapy to any allergen in the year prior to study entry~* Previously received hyposensitization therapy to dust mite, Alternaria, or cockroach for more than 6 months in the 3 years prior to study entry~If participant meets any of these criteria, they are not eligible for the study and may not be reassessed:~* Significant medical illness. More information on this criterion can be found in the protocol.~* Certain medications within 4 weeks of study screening. More information on this criterion can be found in the protocol.~* Known hypersensitivity to any ingredients of omalizumab or related drugs~* Diagnosis of cancer, being investigated for possible cancer, or history of cancer~* Will not allow study physician to manage their asthma~* Does not primarily speak English (or Spanish at centers with Spanish-speaking staff)~* History of severe anaphylactoid or anaphylactic reaction(s)

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Omalizumab (Xolair) + Conventional Therapy (Type: EXPERIMENTAL): Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 60 weeks to participants classified as having moderate to severe asthma. Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP-II, 2002) guidelines, under the management of an asthma specialist health care provider.
- Placebo + Conventional Therapy (Type: PLACEBO_COMPARATOR): Placebo was administered subcutaneously every 2 or 4 weeks over a period of 60 weeks to participants classified as having moderate to severe asthma. Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP-II, 2002) guidelines, under the management of an asthma specialist health care provider.

Based on this trial design, predict the completion outcome and termination type (if applicable).